In 2023, Denmark led in antacid medicine sales per capita, with no growth over the previous year. Italy saw robust growth at 12.89%, and Greece experienced a 4.56% increase. Costa Rica and Estonia both advanced by 8.45%, while Latvia rose by 9.86%. Luxembourg and Slovakia witnessed declines of 2.64% and 7.79%, respectively. Over five years, a varied CAGR reflects differing national consumption trends and market maturity.
Future trends to watch for include:
- Rising demand in emerging markets driven by lifestyle changes and healthcare access.
- Technological advancements and digital therapeutics impacting sales dynamics.
- Increasing competition from alternative therapies, which may influence market share.
Top countries in Antacid Medicine Sales by Country
| # | 9 Countries | US Dollars PPP Per Capita | Last Year | YoY | 5-years CAGR | |
|---|---|---|---|---|---|---|
| 1 | 1 Denmark | 1.9 | 2023 | +5.56% | 0% | View data |
| 2 | 2 Italy | 1.1 | 2023 | +22.22% | +12.89% | View data |
| 3 | 3 Greece | 1 | 2023 | 0% | +4.56% | View data |
| 4 | 4 Costa Rica | 0.9 | 2023 | +12.5% | +8.45% | View data |
| 5 | 5 Estonia | 0.9 | 2023 | 0% | +8.45% | View data |
| 6 | 6 Latvia | 0.8 | 2023 | +14.29% | +9.86% | View data |
| 7 | 7 Luxembourg | 0.7 | 2023 | 0% | -2.64% | View data |
| 8 | 8 Norway | 0.6 | 2023 | 0% | +3.71% | View data |
| 9 | 9 Slovakia | 0.2 | 2023 | 0% | -7.79% | View data |
